

IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF WISCONSIN

NOVOZYMES A/S and  
NOVOZYMES NORTH AMERICA, INC.,

Plaintiffs,

SPECIAL VERDICT: DAMAGES

10-cv-251-bbc

v.

DANISCO A/S,  
GENENCOR INTERNATIONAL WISCONSIN, INC.,  
DANISCO US INC. and DANISCO USA INC.,

Defendants.

We, the jury, for our special verdict, do find as follows:

Question No. 1: What profits, if any, did Novozymes lose on its sales of its Liquozyme products as a result of Danisco's infringement of the '723 patent?

Answer: \$ 8,151,000.00  
Eight million, One Hundred Fifty One Thousand Dollars

Answer Question No. 2.

Question No. 2: Is Novozymes entitled to recover lost profits on sales of glucoamylase as a result of Danisco's infringement of the '723 patent?

Answer: yes  
(Yes or No)

If your answer to Question No. 2 was "yes," answer Question No. 3. If your answer to Question No. 2 was "no," do not answer Question No. 3 and proceed to Question No. 4.

Question No. 3: What profits, if any, did Novozymes lose on its sales of glucoamylase as a result of Danisco's infringement of the '723 patent?

Answer: \$ 8,508,500.<sup>00</sup>  
Eight million, Five Hundred-Eight Thousand-Five Hundred Dollars.

Answer Question No. 4.

Question No. 4: For those infringing sales for which Novozymes has not proven its entitlement to lost profits, what amount of money is a reasonable royalty for Novozymes for Danisco's infringement of the '723 patent?

Answer: \$ 1,560,000<sup>00</sup>  
One Million Five Hundred Sixty Thousand Dollars

Answer Question No. 5.

Question No. 5: Has Novozymes proven by clear and convincing evidence that Danisco's infringement of the '723 patent was willful?

Answer: Yes  
(Yes or No)

Tracy S. Schwantes  
Presiding Juror

Madison, Wisconsin

Dated this 26 day of October, 2011